Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
解讀5位分析師對y-mabs therapeutics的評估
The standing of Y-mAbs Therapeutics...Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish.
在最近的三個月裏，5位分析師分享了他們對y-mabs therapeutics（納斯達克：YMAB）的見解，表達了從看好到看淡的多種觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了他們最近的評級，揭示了過去30天內情緒的變化，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.0, a high estimate of $23.00, and a low estimate of $17.00. Experiencing a 3.09% decline, the current average is now lower than the previous average price target of $21.67.
分析師對12個月價格目標的洞察顯示，平均目標爲21.0美元，高位估計爲23.00美元，低位估計爲17.00美元。目前的平均水平下降了3.09%，現行平均值低於之前的平均價格目標21.67美元。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The standing of Y-mAbs Therapeutics...
y-mabs...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間